FilingReader Intelligence
Haohai Biologics prioritizes returns with steady growth, expanded stock buybacks
March 27, 2025 at 10:17 PM UTC•By FilingReader AI
** Shanghai Haohai Biological Technology Co., Ltd. (SSE:688366) announced its 2024 audited financial results, showcasing steady growth amidst significant industry shifts. Highlighting its commitment to shareholder value, the company proposes a cash dividend of RMB 6.00 per 10 shares, totaling RMB 138,023,048.40, and intends to maintain this robust dividend policy going forward.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Announcement of Shanghai Haohai Biotechnology Co., Ltd. on the appointment of the company's 2025 financial report audit agency and internal control audit agencyMarch 21, 2025 at 01:00 PM UTC
Special statement on the occupation of non-operating funds and other related-party capital transactions of Shanghai Haohai Biotechnology Co., Ltd.March 21, 2025 at 01:00 PM UTC
Shanghai Haohai Biotechnology Co., Ltd. 2024 Annual ReportMarch 21, 2025 at 01:00 PM UTC
Shanghai Haohai Biotechnology Co., Ltd.'s shareholder dividend return plan for the next three years (2025-2027)March 21, 2025 at 12:45 PM UTC
Announcement on the Appointment of Deputy General Manager of Shanghai Haohai Biotechnology Co., Ltd.March 21, 2025 at 12:45 PM UTC
Announcement of Shanghai Haohai Biotechnology Co., Ltd.'s 2024 Profit Distribution PlanMarch 21, 2025 at 01:00 PM UTC
UBS Securities Co., Ltd.'s Verification Opinion on the Deposit and Use of Proceeds Raised by Shanghai Haohai Biotechnology Co., Ltd. in 2024March 21, 2025 at 01:00 PM UTC
Announcement of Shanghai Haohai Biotechnology Co., Ltd. on the Cancellation of Part of the Restricted Stocks Granted but Not Yet Vested in the 2021 A-Share Restricted Stock Incentive PlanMarch 21, 2025 at 01:00 PM UTC
Special certification report on the deposit and use of raised funds of Shanghai Haohai Biotechnology Co., Ltd.March 21, 2025 at 01:00 PM UTC
Internal Control Evaluation Report of Shanghai Haohai Biotechnology Co., Ltd. in 2024March 21, 2025 at 01:00 PM UTC
Special report on the deposit and actual use of raised funds of Shanghai Haohai Biotechnology Co., Ltd. in 2024March 21, 2025 at 01:00 PM UTC
Summary of the 2024 Annual Report of Shanghai Haohai Biotechnology Co., Ltd.March 21, 2025 at 01:00 PM UTC
Shanghai Haohai Biotechnology Co., Ltd.'s 2025 "Quality Improvement, Efficiency Enhancement and Return-Oriented" Action PlanMarch 21, 2025 at 01:00 PM UTC
SSE:688366•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Shanghai Haohai Biological Technology publishes news
Free account required • Unsubscribe anytime